| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Epirubicin HCl (formerly 4'-epidoxorubicin; epiADR; epidoxorubicin; IMI 28; IMI-28; Ellence; Pharmorubicin PFS), the hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin, is a new anthracycline analog and a semisynthetic L-arabino derivative of doxorubicin approved as an anticancer medication. Doxorubicin is a powerful anticancer drug, but its cumulative dose-dependent cardiotoxicity limits its application. Compared to doxorubicin, epirubicin HCl has a better therapeutic index and, at equivalent doses, is less toxic to the heart and blood vessels. Antineoplastic agent epirubicin HCl works by preventing Topoisomerase from doing its job. By intercalating into DNA and interacting with topoisomerase II, epirubicin prevents RNA and protein synthesis as well as DNA replication and repair. In addition, this agent interacts with the lipids in cell membranes to produce toxic free-radical intermediates and lipid peroxidation.
| Targets |
Topoisomerase
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Cell Assay |
A 96-well plate is plated with 500 monolayer Hep G2 cells per well. The following day, epirubicin is added to the medium and the cells are treated. 15% volume of MTT dye solution is added at the conclusion of the incubation times. An equal volume of solubilization/stop solution (dimethylsulfoxide) is added to each well for an additional hour of incubation at 37°C after the first hour of incubation. At 570 nm, the reaction solution's absorbance is measured.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C27H30CLNO11.HCL
|
|
|---|---|---|
| Molecular Weight |
579.98
|
|
| Exact Mass |
579.15
|
|
| Elemental Analysis |
C, 55.91; H, 5.21; Cl, 6.11; N, 2.42; O, 30.34
|
|
| CAS # |
56390-09-1
|
|
| Related CAS # |
|
|
| Appearance |
Red solid powder
|
|
| SMILES |
C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl
|
|
| InChi Key |
MWWSFMDVAYGXBV-FGBSZODSSA-N
|
|
| InChi Code |
InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1
|
|
| Chemical Name |
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
|
|
| Synonyms |
4'-epidoxorubicin HCl; 4'-Epidoxorubicin hydrochloride; IMI28; 4-epi DX; EPI; epi DX; 4-epiadriamycin; 4-epidoxorubicin; 4-epidoxorubicin HCl; epiADR; epidoxorubicin; epidorubicin; IMI 28; IMI-28; brand name: Ellence; Pharmorubicin PFS
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 0.5 mg/mL (0.86 mM) (saturation unknown) in 1% DMSO 99% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: 1.1 mg/mL (1.90 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7242 mL | 8.6210 mL | 17.2420 mL | |
| 5 mM | 0.3448 mL | 1.7242 mL | 3.4484 mL | |
| 10 mM | 0.1724 mL | 0.8621 mL | 1.7242 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01779206 | Active Recruiting |
Drug: Epirubicin Drug: Docetaxel |
Breast Cancer | West German Study Group | May 2012 | Phase 2 Phase 3 |
| NCT03356860 | Active Recruiting |
Drug: Epirubicin Drug: Paclitaxel |
Breast Cancer Luminal B |
Grand Hôpital de Charleroi | April 13, 2017 | Phase 1 Phase 2 |
| NCT04418154 | Active Recruiting |
Drug: epirubicin hydrochloride Drug: Toripalimab |
Triple Negative Breast Cancer | Fudan University | June 9, 2020 | Phase 2 |
| NCT04172259 | Active Recruiting |
Drug: Epirubicin Drug: Docetaxel |
Neoadjuvant Chemotherapy Breast Cancer |
Sun Yat-sen University | January 10, 2019 | Phase 2 |
| NCT01340430 | Active Recruiting |
Drug: Trastuzumab | HER-2 Positive Breast Cancer | Lucia Del Mastro,MD | March 2011 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
